Hepatitis C Virus (HCV) Protease Inhibitor – Pipeline Insights, 2017 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Hepatitis C Virus (HCV) Protease Inhibitor – Pipeline Insights, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Hepatitis C Virus (HCV) Protease Inhibitor-Mechanism of action Insights, 2017 provides comprehensive insights of the ongoing therapeutic research and development across Hepatitis C Virus (HCV) Protease Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Hepatitis C Virus (HCV) Protease Inhibitor by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the Report:

  • The report provides a snapshot of the pipeline development for the Hepatitis C Virus (HCV) Protease Inhibitor
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Hepatitis C Virus (HCV) Protease Inhibitor
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Hepatitis C Virus (HCV) Protease Inhibitor
  • The report also covers the dormant and discontinued pipeline projects related to the Hepatitis C Virus (HCV) Protease Inhibitor

Reasons to Buy:

  • Establish comprehensive understanding of the pipeline activity across this Hepatitis C Virus (HCV) Protease Inhibitor to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Hepatitis C Virus (HCV) Protease Inhibitor therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Note: Please allow up to 48 hours for delivery of this report after payment has been made.

Read more and order at Hepatitis C Virus (HCV) Protease Inhibitor – Pipeline Insights, 2017

NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type, By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), And Segment Forecasts, 2014 – 2025 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type, By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), And Segment Forecasts, 2014 – 2025 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to reach USD 2.09 billion by 2025, according to this new report. Increasing incidence of chronic liver diseases is expected to propel the demand for NASH biomarkers over the forecast period. The National Health and Nutrition Examination Survey recently found that approximately 30% of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone. This disease remains undiagnosed, as a liver can remain fatty without any change in its function. However, it can progress into a serious condition, known as nonalcoholic steatosis that may result in liver failure. NASH is characterized by inflammation and irreversible cell death.

Rising demand for non-invasive diagnostic tools for detection of NASH is another driver of market. Traditionally, liver biopsy is performed to diagnose NAFLD and its degenerative condition, that is, NASH. This technique is expensive and invasive in nature. This disadvantage has led to the development of noninvasive and cost-efficient diagnostic techniques such as biomarker tests. It is observed that many key companies spent significantly on research and development activities to introduce novel biomarker tests. These factors are expected to propel NASH biomarkers market in the coming years.

The drug manufacturers are focusing on tapping unmet medical needs for treatment of NASH to capture additional market share. Strategic collaborations, expansion in developing geographies, and technological advancements are some of the key strategies adopted by existing market players.

Further key findings from the report suggest:
– Serum biomarkers held majority of the revenue share as of 2016 owing to its high efficacy in NASH diagnosis
– Gamma-glutamyl transferase is the serum biomarker that is usually higher in patients with fatty liver diseases, resulting in liver failure
– Increasing list of patients awaiting liver transplantation is a major contributing factor for the growing demand of noninvasive biomarker tests over the forecast period
– Pharmaceutical and contract research industry dominate the end-use segment owing to ample availability of R&D funding and ongoing research projects for the development NASH drugs
– Industry participants are focusing on development of cost-effective solutions, thereby increasing R&D activities for development of novel technologies

* PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.

Read more and order at NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type, By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), And Segment Forecasts, 2014 – 2025

Ornithine Decarboxylase (ODC) Inhibitor – Pipeline Insights, 2017 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Ornithine Decarboxylase (ODC) Inhibitor – Pipeline Insights, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Ornithine Decarboxylase (ODC) Inhibitor-Mechanism of action Insights, 2017 provides comprehensive insights of the ongoing therapeutic research and development across Ornithine Decarboxylase (ODC) Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Ornithine Decarboxylase (ODC) Inhibitor by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the Report:

  • The report provides a snapshot of the pipeline development for the Ornithine Decarboxylase (ODC) Inhibitor
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Ornithine Decarboxylase (ODC) Inhibitor
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Ornithine Decarboxylase (ODC) Inhibitor
  • The report also covers the dormant and discontinued pipeline projects related to the Ornithine Decarboxylase (ODC) Inhibitor

Reasons to Buy:

  • Establish comprehensive understanding of the pipeline activity across this Ornithine Decarboxylase (ODC) Inhibitor to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Ornithine Decarboxylase (ODC) Inhibitor therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Note: Please allow up to 48 hours for delivery of this report after payment has been made.

Read more and order at Ornithine Decarboxylase (ODC) Inhibitor – Pipeline Insights, 2017

Bone Morphogenetic Protein Market Analysis By Type (rhBMP-2, rhBMP-7), By Application (Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial Surgery), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2013 – 2024 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Bone Morphogenetic Protein Market Analysis By Type (rhBMP-2, rhBMP-7), By Application (Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial Surgery), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2013 – 2024 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

The global bone morphogenetic protein (BMP) market size is expected to reach over USD 644.6 million by 2024. Increasing incidence of spinal fusion, trauma, and small bone surgeries coupled with demand for faster bone recovery are the key drivers affirming growth of BMP market.

Low back pain and spinal disc dislocation are some of the most common occupational hazards. Over 75% of such disorders require spinal surgery after noninvasive treatment options are unable to provide any relief. Minimally invasive surgery, shorter hospital stays, and fast recovery are common demands observed among patients. BMP has gained high acceptance among orthopedic surgeons in recent years owing to its ability to cater above mentioned benefits

Sport-related injuries, growing geriatric population, and increasing awareness about osteoinduction products as an alternative to bone grafting are other drivers accentuating market growth. BMP has reported outstanding results over bone graft, such as lack of donor morbidity, extensive surgical procedure, higher recovery time, pain & numbness, and high cost.

Further Key Findings From the Study Suggest:

rhBMP-2 and rhBMP-7 are the commercially available recombinant BMPs. rhBMP-2 is widely known for its high osteoinductive property for faster formation of bone and cartilage in bone fusion procedures

rhBMP-2 held more than half of the market share in 2015. Key attributes contributing toward its growth are high acceptance, wide range of applications, and easier availability in developing countries

rhBMP-7 on the other hand is expected to witness decline in market share over the forecast period owing to factors such as limited usage and discontinuation of OP-1from 2014 by Olympus

Spinal fusion held the largest share in 2015. Increasing cases of sport-related spinal injuries, wide range of product availability, easier usage, and long-term reliability are major factors for the aforementioned dominance.

North America held a significant share of over 65.0% in 2015. High number of orthopedic surgical procedures, and availability of favorable reimbursement policies are drivers that can be attributed to for largest share.

Read more and order at Bone Morphogenetic Protein Market Analysis By Type (rhBMP-2, rhBMP-7), By Application (Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial Surgery), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2013 – 2024

Global End Stage Renal Disease (ESRD) Market with Focus on Dialysis Market (2017-2021 Edition) – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Global End Stage Renal Disease (ESRD) Market with Focus on Dialysis Market (2017-2021 Edition) Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Scope of the Report

The report titled “Global End Stage Renal Disease (ESRD) Market with Focus on Dialysis Market (2017-2021 Edition)” provides an in-depth analysis of the global ESRD market with detailed analysis of market size and growth, market share and economic impact of the industry. The report also provides market size of each of the segments of the market on the basis of the treatment opted by the patients along with the detailed overview of the home dialysis market. The report provides detailed market share analysis of the global dialysis market by players as well.

The report also includes the country analysis of the US and Japan for ESRD market. It provides the analysis of ESRD patient volume along with the kidney transplant and dialysis market on the basis of the volume. The segments of the dialysis market are also analyzed in detail.

The report provides detailed regional analysis of North America, Europe, Middle East and Africa (EMEA), Asia-Pacific and Latin America for the dialysis market. Regional analysis includes market size by volume along with the segments and clinic operators in each region.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry.

Growth of the overall global ESRD market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global dialysis market is stiff and dominated by the big players like Fresenius Medical Care. Further, key players of the dialysis market Baxter and Davita are also profiled with their financial information.

Company Coverage

Fresenius Medical Care
Davita
Baxter

Executive Summary

The global ESRD market increased at a significant CAGR during the span of 5 years, i.e. 2011-2016 and projections are made that the market would rise in the next five years i.e. 2017-2021 tremendously. The upsurge in the market was due to the various reasons such as is diabetic nephropathy, genetic diseases, infection, drugs, traumatic injury, major surgery, etc. The market can be segmented on the basis of treatment as kidney transplant and dialysis. The global dialysis market can be segmented on the basis of products and services. On the basis of products, the market is segmented into hemodialysis and peritoneal dialysis while on the basis of services, the market is segmented into in-center dialysis and home dialysis.

The growth drivers for the market are: rise in diabetic and aging population, upsurge in per capita healthcare expenditure along with the emerging countries such as India, China and Brazil. Despite the market is governed by various growth drivers, there are certain challenges faced by the market such as: disparities in the access to renal transplant therapy, less public awareness and negative societal effects.

Read more and order at Global End Stage Renal Disease (ESRD) Market with Focus on Dialysis Market (2017-2021 Edition)

Primary Biliary Cirrhosis (Pbc) Treatment Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, Corticosteroids, Methotrexate); By Surgery (Liver Transplant); By Diagnosis Test (Blood Test, Imaging, Liver Biopsy) & By Geography-Forecast (2016- – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Primary Biliary Cirrhosis (Pbc) Treatment Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, Corticosteroids, Methotrexate); By Surgery (Liver Transplant); By Diagnosis Test (Blood Test, Imaging, Liver Biopsy) & By Geography-Forecast (2016- Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Primary biliary cirrhosis, also known as primary biliary cholangitis (PBC), is an autoimmune disease of the liver which is relatively rare as compared to other gastro diseases. The advanced stage of PBC is considered as cirrhosis. Identification, diagnosis and treatment differ based on the severity of PBC and patients’ condition. Several diagnosis tests are recommended including blood tests, imaging tests and liver biopsy which further encompass several test methods. The treatment includes medication approach as well as surgical approach. Medical approach includes employment of approved drugs individually or in combination including Ursodeoxycholic Acid, Corticosteroids and Methotrexate which are marketed under different brand names. Obeticholic Acid, new drug is under clinical trials and is expected to be launched in the near future.

The growth of this market is primarily attributed to increasing availability of treatment services and drugs. In addition, to drugs, liver transplantation is performed which completely prevents PBC. Establishment of diagnosis and treatment standards in the recent years boosts the overall service experience as well as treatment outcomes which propels the market growth. Driven by the aforementioned factors, this market is set to reach $XX billion by 2021, growing at a CAGR of XX% during 2016-2021.

North America held a major share of XX% in the PBC drugs market, followed by Europe and APAC. Commercialization of new drugs and expanding specialized services for liver in India and China is set to boost the market revenue in APAC region.

The key players in the PBC Drugs market include:

Sanofi S.A.
Intercept Pharmaceuticals, Inc.
Mylan N.V.
Mankind Pharmaceuticals Pvt. Ltd.

The estimates and forecasts have been derived based on various inputs from primary and secondary sources. Secondary sources such as articles, whitepapers, journals and other has helped to deliver an extensive analysis in this report. Insights related to various regulatory frameworks and clinical studies have been collected from publications by health regulatory agencies. To enhance the accuracy of the estimates, the data has been validated by conducting interviews with industry experts. This report on the PBC treatment market identifies many such insights, new product developments, besides providing a detailed analysis of the key drug companies, treatment service providers and growth potential of the market.

Please Note: The report is to be delivered in 1-2 working days after an order is placed.

Read more and order at Primary Biliary Cirrhosis (Pbc) Treatment Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, Corticosteroids, Methotrexate); By Surgery (Liver Transplant); By Diagnosis Test (Blood Test, Imaging, Liver Biopsy) & By Geography-Forecast (2016-

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) – Pipeline Review, H1 2016 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) – Pipeline Review, H1 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) – Pipeline Review, H1 2016

Summary

‘Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) – Pipeline Review, H1 2016’, provides in depth analysis on Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1)
– The report reviews Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
– The report assesses Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read more and order at Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) – Pipeline Review, H1 2016

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) – Pipeline Review, H1 2016 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) – Pipeline Review, H1 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) – Pipeline Review, H1 2016

Summary

‘Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) – Pipeline Review, H1 2016’, provides in depth analysis on Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1)
– The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics and enlists all their major and minor projects
– The report assesses Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read more and order at Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) – Pipeline Review, H1 2016

Renal Denervation Catheters – Medical Devices Pipeline Assessment, 2017 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Renal Denervation Catheters – Medical Devices Pipeline Assessment, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Renal Denervation Catheters – Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Renal Denervation Catheters – Medical Devices Pipeline Assessment, 2017" provides an overview of Renal Denervation Catheters currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Renal Denervation Catheters pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Renal Denervation Catheters under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Renal Denervation Catheters and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Renal Denervation Catheters under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Read more and order at Renal Denervation Catheters – Medical Devices Pipeline Assessment, 2017

Global Bone Morphogenetic Protein Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Global Bone Morphogenetic Protein Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Bone Morphogenetic Proteins (BMP) are a set of proteins that originate from the human body. Bone morphogenetic proteins are responsible for growth and play a significant role in the maintenance, repair and regulation of bone formation. Bone morphogenetic method helps in the formation of new bones and in the process of bone harvesting. BMP products increase the demand for the bone morphogenetic market as it reduces healing time. The bone morphogenetic proteins market is growing at a fast pace due to the rise in sports and road accidents injuries. The rising number of people who are suffering from spinal injuries together with a rise in surgical rates are primary drivers for the market. According to the National spinal cord injury statistical center, approx 314 million people in the U.S. suffered from spinal cord injuries in 2016.

The global bone morphogenetic protein market has enormous opportunity to increase its demand in emerging countries. The major challenge is the lack of professionals in the field of bone morphogenetic protein market, hampering the BMP market growth.The global bone morphogenetic proteins market is segmented on the basis of type and application. On the basis of type, the global bone morphogenetic protein market is sub divided into recombinant bone morphogenetic protein-7 (rhBMP-7) and recombinant bone morphogenetic protein-2 (rhBMP-2). On the basis of application, the bone morphogenetic proteins market is sub divided into oral maxillofacial surgery, spinal fusion, reconstructive and trauma. Spinal fusion segment shows the largest market share globally due to various factors such as increasing demand for minimally invasive medical procedures, rise in sports injuries, rise in spinal injuries and the growing geriatric population etc.

Geographically, the global bone morphogenetic protein market is bifurcated into North America, Europe, Asia Pacific and Rest of the world. North America is the leading region for the bone morphogenetic protein market followed by Europe. Factors driving demand of bone morphogenetic market are awareness of protein product, adoption of new technology by orthopedic surgeons, increase in geriatric population, prevalence of unhealthy lifestyle and increase in the incidence of spinal injuries.

Some of the key players in the bone morphogenetic protein market are ProSpec; DePuySynthes; Medtronic; R&D Systems; Cellumed Co. Ltd.; Sigma-Aldrich Corporation; and Ember Therapeutics Inc. These companies are using various strategies such as merger, joint venture, acquisition, partnership and product launching to sustain in the market.


Note:
Please allow up to 72 hours for delivery.

Read more and order at Global Bone Morphogenetic Protein Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023